Abstract:Metastatic prostate cancer is associated with considerable morbidity and mortality. Standard treatment for non-metastatic prostate cancer, to prevent metastatic progression, is androgen deprivation therapy (ADT); however, many patients will eventually develop castration-resistant prostate cancer (CRPC), which can prove challenging to treat. Between the stages of non-metastatic androgen-sensitive disease and metastatic CRPC is an intermediate disease state that has been termed non-metastatic CRPC (nmCRPC), which is a heterogeneous, man-made disease stage that occurs after a patient who has no radiological evidence of metastasis shows evidence of cancer progression even after ADT. Awareness of nmCRPC has risen owing to an increased use of ADT and its eventual failure. Men with nmCRPC are at a high risk of progression to mCRPC, with historically few options to halt this process. However, in the past two decades, multiple therapies have been investigated for the treatment of nmCRPC, including endothelin receptor antagonists and bone-targeted therapies, but none has changed the standard of care. In the past decade, the efficacy of androgen receptor pathway-targeting modalities has been investigated. Three novel nonsteroidal antiandrogen agents for treating high-risk nmCRPC have been investigated; the PROSPER, SPARTAN and ARAMIS trials were phase III, randomized, placebo-controlled clinical trials that investigated the efficacy and safety of enzalutamide, apalutamide and darolutamide, respectively. All three therapeutics showed statistically significant improvements in metastasis-free survival, progression to antineoplastic therapy was lengthened and at final analysis, overall survival was significantly improved. The comparative efficacy and safety of all three agents has not yet been investigated in a comprehensive clinical trial, but approval of these medications by the FDA and other regulatory agencies means that providers now have three effective therapeutic options to augment ADT for patients with nmCRPC.

Novel gene-directed enzyme prodrug therapies against prostate cancer

Recent progress in gene-directed enzyme prodrug therapy: an emerging cancer treatment.

Prostate Cancer Relevant Antigens and Enzymes for Targeted Drug Delivery

Development of Provenge for Prostate Carcinoma Therapy

Unleashing novel horizons in advanced prostate cancer treatment: investigating the potential of prostate specific membrane antigen-targeted nanomedicine-based combination therapy

Drug design strategies for the treatment of prostate cancer

The Current Therapeutic Landscape for Metastatic Prostate Cancer

Gene-Directed Enzyme Prodrug Therapy by Dendrimer-Like Mesoporous Silica Nanoparticles against Tumor Cells

Advances in Magnetic Nanoparticle-Driven Delivery of Gene Therapies towards Prostate Cancer

Recent Advances in Prostate Cancer Treatment and Drug Discovery

Quo Vadis Advanced Prostate Cancer Therapy? Novel Treatment Perspectives and Possible Future Directions

Metastatic Prostate Cancer—A Review of Current Treatment Options and Promising New Approaches

Combinatorial approaches of nanotherapeutics for inflammatory pathway targeted therapy of prostate cancer

Novel therapies are changing treatment paradigms in metastatic prostate cancer

Epigenetic mechanism of therapeutic resistance and potential of epigenetic therapeutics in chemorefractory prostate cancer

Pancreatic Cancer: Gene Therapy Approaches and Gene Delivery Systems.

Treatment and trials in non-metastatic castration-resistant prostate cancer

Recent advances and future perspectives in the therapeutics of prostate cancer

Smart nanocarriers for enzyme-activated prodrug therapy

PLGA nanomedical consignation: A novel approach for the management of prostate cancer